by Raynovich Rod | May 8, 2016 | Biopharmaceuticals
Large Cap Biopharma Winners and Losers -Looking for Product Growth We will sift through these metrics and new product news over the coming months to find value in these names. Most should be considered “Market Performers” with some added safety if they...
by Raynovich Rod | Apr 27, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Biotech Bear Market: XLV —A Large Cap Healthcare ETF Outperforms We have compared the performance of top mutual funds in the past and thought it would be interesting to see what happens in a bear market which began in September of 2015. Our last review was in...
by Raynovich Rod | Apr 8, 2016 | Biopharmaceuticals, Macro
Biotech Rally Loses Momentum But Still Up for the Week IBB up 3.37 % , XBI up 5.04% , XLV up 0.77% this week. Investors took profits today despite all of the media focus and renewed excitement for the long term potential of new blockbuster drugs. The rally began...
by Raynovich Rod | Apr 4, 2016 | Biopharmaceuticals
Update 4/6/16 Biotech Rally Picks Up Momentum Today IBB up 4.5%,XBI up 5% Speculative stocks lead the way: BLUE up 10%, VRX up 16.6% ——–Risk on mode continues——— Healthcare Sector Leads the Market Lagging healthcare and biotech...
by Raynovich Rod | Apr 4, 2016 | Biopharmaceuticals
Roche/Genentech Has a Strong Pipeline in Diagnostics and Therapeutics to Drive Moderate Growth in 2016 New Stock Pick: Roche Holding (OTCQX:RHHBY) $30.36 Over the past 3 months we recommended several new buys for the Rayno Biopharma Portfolio emphasizing moderate...
by Raynovich Rod | Mar 9, 2016 | Biopharmaceuticals
Biotech Bear Market Rally is Fading but Traders Are Favored Long Term Concerns on Drug Pricing Remain The biotech sector is still lagging other sectors in 2016 down 20.93% with the IBB compared to the S&P 500 (SPY) down only 2.19%. The IBB rallied over the past...
by Raynovich Rod | Mar 2, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2… Broad Tradable Rally Continues 12:30 PM EST XBI leads IBB today up 4.2% vs 2.9%. XBI at $54 is now up 9.55% over 5 days and well off Feb. 11 bottom of $44. This is a broad rally today with most biotech stocks up and the most speculative stocks are big...
by Raynovich Rod | Feb 22, 2016 | Biopharmaceuticals
2/23 After Close—Energy Rout Burns Biotech Stocks and NASDAQ The red screen dominated except few winners like ZIOPHARM Oncology (ZIOP) up 13.95% on a publication regarding gene editing. Another gene editing stock and recent IPO Editas Medicine (EDIT) was up...
by Raynovich Rod | Feb 16, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Rayno Large Cap Biopharmaceuticals…Part 2…A Stock pickers Market Time to Rebuild Your Portfolio: ABBV, BMY, GILD Below we have summarized selective metrics for large cap biopharmaceutical companies. We began the process of revising and rebalancing our...
by Raynovich Rod | Feb 10, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Macro
Have we reached a tradeable bottom in the biotech bear market? Today’s tape showed good volume but gains faded late in session. NASDAQ up 0.35% XLV up 0.88%-healthcare is the leading sector The biotech market bounced back early today in a broad rally...